MERCK KGAA

Global cell culture market to reach $36,926.80 million by 2027, with a CAGR of 10.9%. Increased awareness and research in cancer and COVID-19 drive demand. Market segmented by product, application, end user, and region. Key players include Becton, Dickinson and Company, Corning Incorporated, and Thermo Fisher Scientific.

Avantor enters 10-year virtual power purchase agreement for 25GWh of renewable energy annually from 2026, supporting three new solar projects in Spain. The agreement reflects Avantor's commitment to reducing greenhouse gas emissions and lowering supply chain costs.

The Biotechnology Contract Manufacturing Market is projected to grow from $16.28 Bn in 2023 to $31.05 Bn by 2031, driven by increasing demand for biopharmaceuticals, rising R&D investments, and advancements in bioprocessing technologies. Key drivers include the use of biologics in various therapeutic areas and the demand for personalized medicine. Challenges include high manufacturing costs, regulatory compliance, and intellectual property risks. Prominent players include Lonza, Samsung Biologics, and Thermo Fisher Scientific.

Illumina welcomed the ECJ's judgment on GRAIL acquisition; Moffitt Cancer Center and AstraZeneca collaborate on cell therapies; Ginkgo Bioworks introduced Ginkgo Automation; UTHealth Houston and OpenAI integrate AI in healthcare; 10x Genomics' platforms used in glioblastoma research; Generate:Biomedicines and Novartis collaborate on protein therapeutics; Firefly Neuroscience advances AI in neuroscience drug development; Scale Bio partners with CZI in the 100 Million Cell Challenge; Oracle launches CancerMPact Treatment Architecture Trends; Verseon's VersAI outperforms Google's AI; MilliporeSigma introduces Mobius ADC Reactor; Gilead and Genesis Therapeutics collaborate on small molecule therapies; Primrose Bio and ExPLoRNA partner on mRNA medicines; UC College of Medicine and Cincinnati Children’s Hospital find new drug discovery methods.

The biotechnology market, valued at USD 1023.92 Million in 2022, is projected to reach USD 10129.16 Billion by 2030 with a CAGR of 29.00%. Driven by personalized medicine, R&D advancements, and investments, key players like Roche and Thermo Fisher Scientific Inc. are leading innovation. Segmented by technology, application, and end-user, the market spans healthcare, agriculture, and industrial biotechnology, among others.

The United States Urinary Tract Cancer Treatment Market is projected to reach USD xx.x billion by 2031, driven by advancements in medical technology, increasing prevalence of urinary tract cancers, and growing awareness about early detection and treatment options. Bladder and kidney cancers dominate the market, with treatment options including surgery, chemotherapy, radiation therapy, and immunotherapy. Future growth is expected with advancements in precision medicine, targeted therapies, and immunotherapies.

DelveInsight's 'Adrenoleukodystrophy Pipeline Insight, 2024' report details 11+ treatment therapies by 10+ companies, including Autobahn Therapeutics, Viking Therapeutics, and SwanBio Therapeutics. Emerging therapies like ABX-002, VK0214, and SBT101 are expected to impact the market. Minoryx Therapeutics plans to re-examine Nezglyal's approval after CHMP's refusal.

Pharmaceutical industry inefficiencies stem from high costs per drug approval, frequent C-level executive changes, and strategic R&D restructuring unrelated to science. AI-drug discovery companies should commit to programs until Phase I completion to avoid waste and maximize patient benefit.

Separation Systems For Commercial Biotechnology Market is projected to double by 2032, driven by demand for biologics and advancements in downstream processing. Key players include Agilent Technologies, Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories Inc, Merck KGaA, Perkin Elmer Inc, Sartorius AG, Shimadzu Corp, Thermo Fisher Scientific Inc, and Others. The market is expected to grow at a CAGR of 13.8% from 2024 to 2032.

The global cell expansion market is projected to grow at a CAGR of 12.1% from 2024 to 2034, reaching $40.1 billion by 2034. AI and ML are revolutionizing the process, while decentralized healthcare drives portable technologies. Key players include Thermo Fisher Scientific, Miltenyi Biotec, and Merck KGaA. Stem cells and bioreactors dominate the market, with biotechnology and pharmaceutical companies leading in end-user segments. North America and Europe are major regions, with Asia Pacific witnessing rapid growth.